[New treatments of hemorrhagic rectocolitis]
- PMID: 2901821
[New treatments of hemorrhagic rectocolitis]
Abstract
The treatment of ulcerative colitis has benefited from the development of new molecules (azo-disalicylates) or new galenic forms (Pentasa, Azacol...) permitting, via oral administration, to supply the colon with 5-aminosalicylic acid without the sulfapyridine with which it was combined in salazosulfapyridine and was responsible for most side effects. Pentasa and steroids which are moderately absorbed by the colonic mucosa (tixocortol pivalate, prednisolone metasulfabenzoate may also be used un an enema form or, for some, in ointment form, to treat mild attacks in the distal forms of the disease.
Similar articles
-
[Salazosulfapyridine or 5-aminosalicylic acid].Ned Tijdschr Geneeskd. 1987 May 30;131(22):931-4. Ned Tijdschr Geneeskd. 1987. PMID: 2885762 Dutch. No abstract available.
-
Sulfasalazine and new analogues.Am J Gastroenterol. 1986 Feb;81(2):141-4. Am J Gastroenterol. 1986. PMID: 2868653 Review. No abstract available.
-
New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.Gastroenterol Clin North Am. 1989 Mar;18(1):43-50. Gastroenterol Clin North Am. 1989. PMID: 2646221 Review.
-
Comparable efficacy of oral 5-aminosalicylic acid (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission.Isr J Med Sci. 1990 Jan;26(1):47-9. Isr J Med Sci. 1990. PMID: 1968895 No abstract available.
-
Will there be a next generation of sulfasalazine?Gastroenterology. 1982 Nov;83(5):1138-41. Gastroenterology. 1982. PMID: 6126420 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical